{
    "id": 25066,
    "fullName": "EZR - ERBB4",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EZR - ERBB4 results from the fusion of EZR and ERBB4, which leads to constitutive phosphorylation of Erbb4, resulting in transformation in cell culture and tumor formation in animal models (PMID: 24727320).",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7430,
        "geneSymbol": "EZR",
        "terms": [
            "EZR",
            "CVIL",
            "CVL",
            "HEL-S-105",
            "VIL2"
        ]
    },
    "variant": "EZR - ERBB4",
    "createDate": "08/02/2016",
    "updateDate": "08/02/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2066,
                "geneSymbol": "ERBB4",
                "terms": [
                    "ERBB4",
                    "ALS19",
                    "HER4",
                    "p180erbB4"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 7546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited Erbb4 signaling and anchorage-independent growth of transformed cells over expressing EZR - ERBB4 in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 25832,
                "profileName": "EZR - ERBB4"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7547,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited Erbb4 signaling and anchorage-independent growth of transformed cells over expressing EZR - ERBB4 in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 25832,
                "profileName": "EZR - ERBB4"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7548,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 inhibited Erbb4 signaling and anchorage-independent growth of transformed cells over expressing EZR - ERBB4 in culture (PMID: 24727320).",
            "molecularProfile": {
                "id": 25832,
                "profileName": "EZR - ERBB4"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6416,
                    "pubMedId": 24727320,
                    "title": "Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24727320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25832,
            "profileName": "EZR - ERBB4",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}